If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
677.00    95.00 (16.32%)
Bid:
682.00
Ask:
685.00
Spread: 3.00 (0.44%)
Market Cap: £589.84m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

Today 07:00

RNS Number : 2212L
Victrex PLC
07 July 2026
 

7 July 2026

Victrex plc - Q3 trading update

'Momentum continues in Q3: full year guidance maintained'

Victrex plc is an innovative world leader in high performance polymer solutions, focused on the end markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Today's trading update covers the third quarter (Q3) of FY 2026, from 1 April 2026 to 30 June 2026.

 

Q3 and year-to-date (YTD) performance summary

 

·

Q3 (3 months ended 30 June 2026) Group revenues grew 18% vs Q3 2025, driven by Group volumes increasing by 17%. Year-on-year performance reflects momentum continuing from Q2 in Sustainable Solutions end markets, supported by some stabilisation in Medical.

·

At divisional level, Aerospace and Electronics were the main drivers of growth in Sustainable Solutions. Aerospace had a much weaker prior year comparator following industry supply chain backlogs in 2025.

·

Average selling price (ASP) of £68/kg was in line with the prior year (Q3 2025: £68/kg).

·

Year to date (YTD) Group revenues increased by 7%, with YTD Group volumes up 10%.

 

 

Quarter ended 30 June

 (Q3)

Nine months ended 30 June

(YTD)

2026

 

2025

% change

 

2026 2025 % change

Revenue (£m)

84.5

71.5

+18%

231.6 217.3 +7%

Sales volume (tonnes)

1,238

1,057

+17%

3,375 3,075 +10%

 

Good progress with Profit Improvement Plan and Unlocking Victrex's Potential

Since the start of 2026, we have made good progress in taking actions to simplify the business, to refresh our leadership team and decentralise our organisation, enabling us to become closer to our customers. Our headcount reduction of c10% of roles will start to see initial benefits in our final quarter (Q4), with most employees directly affected having left the business during Q3. We remain on track for annualised cost savings of at least £10m, which will be fully realised in FY 2027. As previously communicated, cash exceptional items for FY 2026 are expected to be approximately £10m.

 

Financial position

Net debt at 30 June 2026 was £43.0m, with cash of £27.5m. This is after payment of the Group's FY 2026 interim dividend (13.42p/share), totalling approximately £12m.

 

Outlook: full-year guidance maintained

 

Dr James Routh, Chief Executive Officer of Victrex, said:

 

"Q3 maintained the positive momentum we saw through our second quarter. Compared to the prior year, revenue growth was driven by improvement across several end markets, particularly Aerospace and Electronics, with some stabilisation in Medical.

 

In our final quarter (Q4), whilst we will start to see initial cost savings as part of our Profit Improvement Plan, we remain mindful of normal seasonality and wider macroeconomic conditions including the potential implications for global demand and energy costs. Our full year guidance is therefore unchanged and as previously communicated, the Board expects FY 2026 underlying PBT to be in the range of £42m-£44m.

 

Our growth opportunities remain strong across a broad range of end markets and geographies. With a clear and differentiated value proposition, unmatched expertise in PEEK and world class applications know-how, we are focused on driving significant improvement in profitability over the medium term."

 

Capital Markets Event 2026: Unlocking Victrex's Potential

 

The Group will host its 2026 Capital Markets Event 'Unlocking Victrex's Potential' at Investec, 30 Gresham Street, London, EC2V 7QP, UK, on Thursday 24th September starting at 15.00 UK time, followed by an informal reception at 18.00.

 

This event will focus on:

· Progress in our Profit Improvement Plan

· The addressable market and delivering new application opportunities for VictrexTM PEEK

· Our revised operating model and refreshed leadership team

· Our roadmap to significant improvement in profitability over the medium term

 

Victrex plc:

 

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG 

+44 (0) 7809 595831

Ian Melling, Chief Financial Officer

+44 (0) 1253 897700

Dr James Routh, Chief Executive Officer

+44 (0) 1253 897700

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the end-markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to energy operations and medical devices. With over 40 years' experience, our products shape future performance for our customers and our end-markets, enable environmental and societal benefit and drive value for our shareholders. Find out more at www.victrexplc.com

 

Forward looking statements:

This announcement has been prepared solely to provide additional information to the shareholders of Victrex plc, to meet the requirements of the FCA's Disclosure and Transparency Rules. It should not be relied on by any other party, for any other purposes. Forward-looking statements have been made by the directors in good faith, using information available up until the date on which they approved this statement. Forward-looking statements should be regarded with caution, because of the inherent uncertainties in economic trends and business risks.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUGPMUPQGQQ
Date   Source Headline
7th Jul 20267:00 amRNSTrading Statement
2nd Jul 20262:33 pmRNSBlock Listing Application
30th Jun 20263:41 pmRNSTotal Voting Rights
30th Jun 20263:15 pmRNSHolding(s) in Company
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.